1. Volume 370, Issue 9594, Pages 1209-1218 (October 2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial 
Prof Thierry Facon, MD, Jean Yves Mary, PhD, Cyrille Hulin, MD, Lotfi Benboubker, MD, Prof Michel Attal, MD, Brigitte Pegourie, MD, Marc Renaud, MD, Prof Jean Luc Harousseau, MD, Gaëlle Guillerm, MD, Carine Chaleteix, MD, Mamoun Dib, MD, Laurent Voillat, MD, Hervé Maisonneuve, MD, Jacques Troncy, MD, Véronique Dorvaux, MD, Prof Mathieu Monconduit, MD, Claude Martin, MD, Prof Philippe Casassus, MD, Jérôme Jaubert, MD, Henry Jardel, MD, Prof Chantal Doyen, MD, Brigitte Kolb, MD, Bruno Anglaret, MD, Prof Bernard Grosbois, MD, Ibrahim Yakoub-Agha, MD, Claire Mathiot, MD, Prof Hervé Avet-Loiseau, MD 
The Lancet 
Volume 370, Issue 9594, Pages (October 2007)
DOI: /S (07)
Copyright © 2007 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
MP=melphalan and prednisone. MPT=melphalan and prednisone with thalidomide. MEL100=reduced-intensity autologous stem cell transplantation using melphalan 100 mg/m2.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions

3. Figure 2
Overall survival (A), progression-free survival (B), and survival after progression (C) as a function of treatment
MP=melphalan and prednisone. MPT=melphalan and prednisone with thalidomide. MEL100=reduced-intensity autologous stem cell transplantation using melphalan 100 mg/m2. Date of point was Jan 8, O/N=number of events (death, progression or death without progression, death after progression)/number of patients.
The Lancet  , DOI: ( /S (07) )
Copyright © 2007 Elsevier Ltd Terms and Conditions